Endometrial cancer treatment has entered a new era, combining time-tested surgical approaches with cutting-edge therapies that target the unique characteristics of each person’s tumor, offering renewed hope for better outcomes and quality of life.

Fighting Endometrial Cancer: A Journey Through Modern Treatment

When someone receives an endometrial cancer diagnosis, understanding the treatment landscape becomes crucial. The main goal of treatment is to remove or destroy cancer cells, prevent the disease from spreading, and help patients maintain the best possible quality of life during and after therapy. Treatment decisions depend on several factors including how far the cancer has spread, the specific type of cancer cells involved, and the patient’s overall health and personal preferences.^[1]

Medical professionals now recognize that endometrial cancer is not a single disease but rather a collection of different cancer types with distinct behaviors. This understanding has revolutionized treatment approaches. Doctors use both established therapies approved by medical societies and explore promising new options through clinical research. The treatment plan often involves multiple healthcare providers working together, including gynecologic oncologists, medical oncologists, radiation specialists, and supportive care teams.^[2]

Surgery remains the foundation of treatment for most patients, particularly when the cancer is caught early. However, the treatment journey doesn’t end there. Depending on the stage and type of cancer, additional therapies may be needed to reduce the risk of the cancer returning or to treat cancer that has already spread. These supplementary treatments can include radiation therapy, chemotherapy, hormone therapy, or newer approaches like immunotherapy and targeted therapy.^[10]

Standard Treatment Options for Endometrial Cancer

The cornerstone of endometrial cancer treatment is surgery, specifically a procedure called hysterectomy, which means removal of the uterus. For most patients with endometrial cancer, the surgical procedure also includes removal of both fallopian tubes and ovaries, a combination known as total hysterectomy with bilateral salpingo-oophorectomy. During the same operation, surgeons often examine and remove nearby lymph nodes from the pelvis and abdomen to determine if cancer has spread beyond the uterus. This comprehensive surgical approach both treats the cancer and provides critical information about its stage, which guides decisions about any additional therapy needed.^[12]

Modern surgical techniques have evolved significantly. Many patients are now candidates for minimally invasive surgery, which uses small incisions rather than a large abdominal cut. This can be done through standard laparoscopy or with robotic assistance. Studies have shown that when patients are appropriately selected for minimally invasive approaches, their cancer outcomes are just as good as with traditional open surgery. The advantages of minimally invasive surgery include less pain after the procedure, shorter hospital stays, faster return to normal activities, and fewer complications related to the surgical wound.^[12]

After surgery, the treatment team reviews all the information gathered during the operation. For some patients with early-stage cancer and favorable characteristics, no additional treatment may be needed. However, for those with higher-risk features, supplementary therapies are recommended to reduce the chance of cancer returning. These decisions are based on national guidelines developed by medical societies and expert panels.^[11]

Radiation therapy uses high-energy beams to kill cancer cells. It can be delivered in two main ways: external beam radiation, where a machine directs radiation at the pelvis from outside the body, or internal radiation called brachytherapy, where radioactive material is placed inside the vagina near where cancer cells might remain. Radiation therapy is often recommended for patients whose cancer had spread into the muscle wall of the uterus or beyond. The treatment typically runs for several weeks, with sessions occurring five days per week. Side effects can include fatigue, skin irritation in the treatment area, diarrhea, and changes to the vaginal tissues.^[11]

Chemotherapy involves medications that travel through the bloodstream to kill cancer cells throughout the body. It’s typically used for patients with advanced-stage cancer or cancer that has come back after initial treatment. Common chemotherapy drugs for endometrial cancer include carboplatin and paclitaxel, often given together. These medications are usually administered through a vein in cycles, with treatment days followed by rest periods to allow the body to recover. A complete course may last three to six months. Chemotherapy side effects vary but can include nausea, hair loss, fatigue, increased infection risk due to lowered white blood cell counts, and numbness or tingling in the hands and feet, a condition called peripheral neuropathy.^[11]

Hormone therapy takes advantage of the fact that some endometrial cancer cells depend on hormones to grow. These treatments use synthetic forms of the hormone progesterone, such as megestrol acetate or medroxyprogesterone acetate, to slow or stop cancer growth. Hormone therapy is most often used for cancer that has spread to other parts of the body or has returned after initial treatment. It’s also sometimes offered to younger women with very early-stage cancer who wish to preserve their ability to have children, though this approach requires very careful monitoring. Hormone therapy typically has fewer side effects than chemotherapy, but can cause weight gain, fluid retention, increased blood sugar levels, and blood clot risk.^[11]

Treatment Innovations in Clinical Trials

The landscape of endometrial cancer treatment is rapidly changing thanks to groundbreaking research. Scientists have discovered that endometrial cancer can be divided into different molecular subtypes based on specific genetic changes within the cancer cells. This classification goes beyond the traditional way of categorizing cancers by how they look under a microscope. Understanding these molecular characteristics has opened doors to precision medicine approaches where treatment is tailored to the specific molecular features of each patient’s tumor.^[13]

One of the most exciting advances involves immune checkpoint inhibitors, a type of immunotherapy that helps the body’s own immune system recognize and attack cancer cells. Cancer cells can sometimes hide from the immune system by using special proteins called checkpoint proteins. Checkpoint inhibitors block these proteins, essentially removing the cancer’s invisibility cloak. Three immune checkpoint inhibitors have gained approval for treating advanced endometrial cancer: dostarlimab-gxly (sold as Jemperli), durvalumab (Imfinzi), and pembrolizumab (Keytruda).^[16]

These immunotherapy drugs work particularly well in tumors with certain molecular features. One such feature is called microsatellite instability or MSI, which occurs when the cells’ DNA repair machinery isn’t working properly. Another is high tumor mutational burden, meaning the cancer cells have accumulated many genetic mistakes. Patients undergo special testing to determine if their cancer has these characteristics, which helps doctors predict whether immunotherapy will be effective. These tests look at the tumor tissue removed during biopsy or surgery.^[16]

Checkpoint inhibitors are typically given through intravenous infusion every few weeks. They can be used alone or combined with chemotherapy, depending on the situation. The side effects of immunotherapy differ from traditional chemotherapy because instead of directly poisoning cancer cells, these drugs activate the immune system. This activation can sometimes cause the immune system to attack normal organs, leading to inflammation of the lungs, liver, intestines, or hormone-producing glands. Most patients tolerate immunotherapy well, but careful monitoring is essential to catch and treat any immune-related side effects early.^[16]

Targeted therapy represents another innovative treatment strategy. These drugs target specific proteins or pathways that cancer cells use to grow and survive. Lenvatinib (Lenvima) is a targeted therapy approved for endometrial cancer. It works as a kinase inhibitor, blocking certain enzymes that cancer cells need to form new blood vessels and to grow. Without these blood vessels, tumors struggle to get the oxygen and nutrients they need. Lenvatinib is usually given in combination with pembrolizumab for patients with advanced endometrial cancer that has worsened despite previous treatment. The medication comes as pills taken once daily. Side effects can include high blood pressure, diarrhea, fatigue, decreased appetite, joint and muscle pain, and skin reactions on the hands and feet.^[16]

Clinical trials are investigating other targeted therapies as well. Some focus on blocking hormone receptors in new ways, going beyond traditional progesterone-based hormone therapy. For example, researchers are studying whether drugs that block estrogen receptors, similar to those used in breast cancer treatment, might benefit certain patients with endometrial cancer. Other studies examine drugs that target specific genetic mutations found in some endometrial cancers, such as changes in the PIK3CA or PTEN genes.^[17]

An unexpected finding from research involves metformin, a medication commonly used to treat type 2 diabetes. Early studies suggest this drug might have anti-cancer properties in endometrial cancer. Scientists believe metformin works by affecting the body’s metabolism and insulin signaling pathways, which are often disrupted in endometrial cancer. While metformin is not yet standard treatment for cancer, clinical trials are exploring whether adding it to conventional therapies might improve outcomes.^[16]

Clinical trials evaluate new treatments through phases. Phase I trials focus primarily on safety, determining the right dose of a new drug and watching for side effects in a small group of patients. Phase II trials expand testing to more patients to see if the treatment actually works against the cancer and to gather more safety information. Phase III trials compare the new treatment against current standard therapy in large groups of patients to determine if the new approach is better. These trials are conducted at medical centers across countries including the United States, Europe, and increasingly in other regions worldwide.^[13]

Patients interested in clinical trials should discuss options with their oncology team. Eligibility for trials depends on many factors including cancer stage, previous treatments received, overall health status, and the specific molecular characteristics of the tumor. Clinical trials offer access to cutting-edge treatments before they become widely available, and participants contribute valuable information that advances cancer research for future patients.^[13]

Most common treatment methods

• Surgery
  • Total hysterectomy with bilateral salpingo-oophorectomy removes the uterus, cervix, fallopian tubes, and ovaries
  • Lymph node removal from pelvis and abdomen helps determine cancer stage
  • Minimally invasive techniques include laparoscopy and robotic-assisted surgery
  • Open surgery through abdominal incision used when minimally invasive approaches aren’t suitable
• Radiation therapy
  • External beam radiation directs high-energy beams from outside the body toward the pelvis
  • Brachytherapy places radioactive material inside the vagina near potential remaining cancer cells
  • Treatment typically runs for several weeks with daily sessions
  • Used after surgery for patients with higher-risk cancer features
• Chemotherapy
  • Carboplatin and paclitaxel are commonly used drugs, often given together
  • Administered intravenously in cycles over three to six months
  • Recommended for advanced-stage cancer or recurrent disease
  • Works throughout the body to kill cancer cells
• Hormone therapy
  • Uses progesterone-like medications such as megestrol acetate or medroxyprogesterone acetate
  • Slows cancer growth in tumors dependent on hormones
  • Often used for advanced or recurrent cancer
  • May preserve fertility in selected young women with very early-stage disease
• Immunotherapy
  • Dostarlimab-gxly (Jemperli), durvalumab (Imfinzi), and pembrolizumab (Keytruda) approved for advanced endometrial cancer
  • Works by blocking checkpoint proteins that hide cancer from immune system
  • Most effective in tumors with microsatellite instability or high tumor mutational burden
  • Can be used alone or combined with chemotherapy
• Targeted therapy
  • Lenvatinib (Lenvima) blocks enzymes cancer cells need to form blood vessels and grow
  • Usually combined with pembrolizumab for advanced endometrial cancer
  • Taken as daily pills rather than intravenous infusion
  • Research ongoing for other targeted drugs addressing specific genetic mutations

Living With Endometrial Cancer During and After Treatment

The journey with endometrial cancer extends beyond medical treatments. Maintaining overall health and wellbeing plays a vital role in managing the disease and recovering from treatment. Nutrition becomes especially important, as eating well helps the body cope with treatment side effects and supports healing. Healthcare providers often recommend consulting with a registered dietitian who specializes in oncology to develop an eating plan tailored to individual needs and treatment schedules.^[22]

A healthy diet for endometrial cancer patients emphasizes plant-based foods rich in vitamins, minerals, and antioxidants. Fruits and vegetables, particularly those with deep colors like red, orange, yellow, and dark green, contain compounds that help fight inflammation and protect cells from damage. The Mediterranean dietary pattern, which includes plenty of fruits, vegetables, legumes, whole grains, and healthy fats while limiting processed meats and sugary foods, has shown promise in research related to endometrial cancer risk and outcomes.^[22]

Staying at a healthy body weight matters because obesity is one of the strongest risk factors for developing endometrial cancer and may also affect outcomes after diagnosis. However, patients should focus on preventing weight loss during active treatment rather than trying to lose weight, as maintaining strength and nutrition is the priority. Regular physical activity, as tolerated and approved by the medical team, helps maintain muscle mass, reduces fatigue, improves mood, and supports overall health.^[5]

Emotional and psychological support forms another critical component of comprehensive cancer care. A diagnosis of endometrial cancer naturally brings up many emotions including fear, anxiety, sadness, and uncertainty. Building a strong support system helps patients navigate these challenges. This network might include family members, friends, professional counselors or therapists, support groups with other cancer patients, and patient navigators who help coordinate care and connect people with resources. Many organizations dedicated to gynecologic cancers offer support services, educational programs, and opportunities to connect with others who understand the experience firsthand.^[19]

After completing initial treatment, patients enter a phase of surveillance and follow-up care. Regular check-ups monitor for any signs of cancer recurrence and manage any long-term effects of treatment. These appointments typically include physical examinations with pelvic exams and may involve imaging tests. The frequency of follow-up visits is usually higher in the first few years after treatment and then gradually decreases if no problems arise. Patients should promptly report any concerning symptoms between scheduled visits, such as abnormal vaginal bleeding, pelvic pain, unexplained weight loss, or persistent fatigue.^[21]

Understanding the possibility of recurrence helps patients stay vigilant without living in constant fear. Endometrial cancer can sometimes return after successful treatment, appearing in the pelvis, vagina, lymph nodes, or other parts of the body. The risk of recurrence depends on the original stage and characteristics of the cancer. If cancer does come back, treatment options are available, and many patients with recurrent disease benefit from newer therapies including immunotherapy, targeted therapy, or clinical trials testing novel approaches.^[20]

The healthcare team for endometrial cancer often includes many specialists working together. The gynecologic oncologist leads surgical care and overall coordination. Medical oncologists manage chemotherapy, immunotherapy, and targeted therapy. Radiation oncologists oversee radiation treatment. Oncology nurses provide education, help manage symptoms, and serve as a point of contact throughout treatment. Social workers assist with practical matters like transportation, support programs, and counseling. Patient navigators help coordinate care and remove barriers to treatment. This team approach ensures comprehensive, coordinated care that addresses all aspects of the disease.^[19]

Many patients find it helpful to keep records of their cancer journey, including pathology reports, treatment summaries, and lists of medications. Creating a survivorship care plan that outlines what treatments were received, potential long-term effects to watch for, and a schedule for follow-up care provides a valuable reference for both patients and their healthcare providers. This becomes especially important if care involves multiple doctors or facilities.^[21]